Tissue Regenix (LSW GR)

Analysis

Health Care • United Kingdom

Tissue Regenix Group is an international medical technology company specializing in regenerative products using its dCELL® and BioRinse™ platform technologies. These technologies address soft tissue and bone allograft needs through products like DermaPure® for soft tissue repair and ConCelltrate® for bone regeneration, primarily serving the BioSurgery, Orthopaedics, and Dental markets. The company was founded in 2006 in Leeds, UK, and has operations in the UK and US.

Refresh

Exchange Announcement • 23 Dec 2025 00:08

Result of General Meeting and Cancellation

Exchange Announcement • 08 Dec 2025 15:00

Update re. proposed cancellation of shares

Exchange Announcement • 04 Dec 2025 22:40

Proposed £17.5m CLN raise, cancellation of Trading

Exchange Announcement • 01 Dec 2025 15:00

Further re. financial update and funding plans

Exchange Announcement • 07 Nov 2025 15:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Result of General Meeting and Cancellation

Update re. proposed cancellation of shares

Proposed £17.5m CLN raise, cancellation of Trading

Further re. financial update and funding plans

Financial update and funding plans